KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) EBT (2017 - 2026)

Moderna (MRNA) has disclosed EBT for 10 consecutive years, with -$1.3 billion as the latest value for Q1 2026.

  • For Q1 2026, EBT fell 38.38% year-over-year to -$1.3 billion; the TTM value through Mar 2026 reached -$3.1 billion, up 7.87%, while the annual FY2025 figure was -$2.8 billion, 23.26% up from the prior year.
  • EBT hit -$1.3 billion in Q1 2026 for Moderna, down from -$799.0 million in the prior quarter.
  • Across five years, EBT topped out at $4.2 billion in Q1 2022 and bottomed at -$2.0 billion in Q3 2023.
  • Average EBT over 5 years is -$122.1 million, with a median of -$799.0 million recorded in 2025.
  • Year-over-year, EBT surged 235.63% in 2022 and then crashed 1791.43% in 2024.
  • Moderna's EBT stood at $1.7 billion in 2022, then plummeted by 95.77% to $70.0 million in 2023, then plummeted by 1791.43% to -$1.2 billion in 2024, then soared by 32.52% to -$799.0 million in 2025, then crashed by 66.96% to -$1.3 billion in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$1.3 billion, -$799.0 million, and -$187.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.